{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:15:31Z","timestamp":1753892131270,"version":"3.41.2"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Drug-induced pulmonary arterial hypertension (PAH) has been widely reported but PAH caused by leflunomide is very rare. Here we report the case of a young man with nephrotic syndrome treated with leflunomide for 5\u00a0years before being admitted to our hospital for dyspnea. After discontinuing leflunomide treatment for 4\u00a0months, both the dyspnea and pulmonary artery systolic pressure improved. Right heart catheterization showed in a significant decrease in pulmonary vascular resistance and pulmonary artery pressure 4 months later. Because persistent PAH can lead to right heart failure and even death, identifying and excluding the risk factors is critical; discontinuing leflunomide until a definite cause is identified is highly recommended.<\/jats:p>","DOI":"10.3389\/fphar.2022.992457","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T08:37:54Z","timestamp":1666082274000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Leflunomide-induced pulmonary arterial hypertension in a young man with nephrotic syndrome: A case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoqin","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sisi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12012-012-9153-3","article-title":"Leflunomide- induced pulmonary hypertension in a young woman with rheumatoid arthritis: A case report","volume":"12","author":"Alvarez","year":"2012","journal-title":"Cardiovasc. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/rheumatology\/keg038","article-title":"The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes","volume":"42","author":"Burger","year":"2003","journal-title":"Rheumatol. Oxf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jbspin.2017.12.014","article-title":"Pulmonary arterial hypertension in four patients treated by leflunomide","volume":"85","author":"Coirier","year":"2018","journal-title":"Jt. Bone Spine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1136\/adc.2003.039289","article-title":"Increased pulmonary arterial pressure in children with nephrotic syndrome","volume":"89","author":"Du","year":"2004","journal-title":"Arch. Dis. Child."},{"key":"B5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS) : Endorsed by: Association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT)","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur. Heart J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1172\/JCI77656","article-title":"EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho\/TGF- \u03b2 1 signaling","volume":"125","author":"Lu","year":"2015","journal-title":"J. Clin. Investig."},{"key":"B7","doi-asserted-by":"publisher","first-page":"A3827","DOI":"10.1164\/ajrccm-conference.2020.201","article-title":"Initial combination therapy with macitentan and tadalafil in pulmonary arterial hypertension: A retrospective cohort study","volume":"201","author":"Marinescu","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1093\/rheumatology\/keh328","article-title":"Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide","volume":"43","author":"Martinez Taboada","year":"2004","journal-title":"Rheumatol. Oxf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1513\/AnnalsATS.202008-913OC","article-title":"Association between leflunomide and pulmonary hypertension","volume":"18","author":"Palasset","year":"2021","journal-title":"Ann. Am. Thorac. Soc."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.992457\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T08:37:56Z","timestamp":1666082276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.992457\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":9,"alternative-id":["10.3389\/fphar.2022.992457"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.992457","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,10,17]]},"article-number":"992457"}}